| This week's sponsor is Premier Research. | | | Overcoming Risk in Oncology Drug Development
Oncology drug development is fraught with obstacles and risks, and you must carefully plan each step. Click here for tips on finding the fast track. Premier Research. It's what we do. Best. |
Today's Rundown Iannone walks out on troubled Immunomedics a year after taking CMO job Biopharma converts 24% of NMEs to drugs, with Celgene bringing up the rear: report Regeneron bags Calixar tech to support antibody discovery effort [Sponsored] Emerging Biotechs are Here to Stay; CROs Models Will Permanently Change Bicycle files for $86M IPO to fund trials of novel drug conjugates New phase 3 data paint fuller picture for Horizon's teprotumumab: AACE FBI raids uBiome’s San Francisco HQ over insurance billing practices: reports Featured Story | | | Monday, April 29, 2019 Last April, Immunomedics scored a former AstraZeneca cancer executive as its research lead; one year down the line, and Robert Iannone, M.D., is moving on as the biotech attempts to rebound from an FDA rejection and the loss of its CEO. |
|
|
Top Stories Monday, April 29, 2019 Though biopharmas seem to be using their R&D dollars more effectively, they are only converting 24% of new molecular entities to approved drugs, SVB Leerink found in a five-year analysis of eight biopharma companies. Monday, April 29, 2019 Regeneron has bought the right to use Calixar’s membrane protein technology to discover antibodies against an undisclosed target. The deal gives Regeneron access to technology designed to conserve the functional and structural integrity of targets. Monday, April 29, 2019 The prominence of emerging biotech looms large on the drug development landscape. CROs continue to adjust their core competencies and cultural mindset to tailor services for specific biotech needs. Monday, April 29, 2019 Bicycle Therapeutics has filed to raise up to $86 million in a Nasdaq IPO. The British biotech wants the money to prepare for phase 2 and 3 clinical trials of its lead anticancer candidate, BT1718. Friday, April 26, 2019 Horizon Pharma presented new data from a phase 3 study of its inflammatory eye drug teprotumumab that dig deeper into how fast the drug works and how it stacks up against the current treatment: eye surgery. Monday, April 29, 2019 The FBI has raided the San Francisco headquarters of sequencing-based test provider uBiome, as part of a snowballing investigation into the company’s billing practices by law enforcement agencies, state regulators and insurance companies. The Friday morning search was first reported by The Wall Street Journal. | This week's sponsor is ExL Events. | | | |
Resources Sponsored by: AlphaSense What is agile competitive intelligence, and how can help healthcare researchers stay ahead of the curve? Sponsored by: Outer Edge Technology Learn how the cloud can support the performance and security requirements for validated, mission-critical applications historically designed and implemented exclusively via on-premises deployment. Sponsored by: Elemental Machines Learn how cloud-connected IoT sensors are transforming operations in leading life science labs. Read our white paper “The Smart Lab”. Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BioBasics: Biotech For The Non-Scientist May 8-9, 2019 | New York, NY Drug Development Immersion May 16-17, 2019 | Boston, MA 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA FierceBiotech Executive Breakfast at BIO 2019 – Getting Real: The Changing Tide on Real-World Evidence in Drug Development June 5, 2019 | Philadelphia, PA World Pharma Week June 17-20, 2019 | Seaport World Trade Center | Boston, MA Medical Sensors Design Conference June 25, 2019 | McEnery Convention Center | San Jose, CA Sensors Expo & Conference June 25-27, 2019 | McEnery Convention Center | San Jose, CA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 